Money page · tirzepatide only · value per expected point
Most affordable tirzepatide in 2026: dollars per expected point, run on the re-verified field
NexLife status, re-read September 17, 2026. The standard cards this site audited on August 14, 2026 — tirzepatide $169 / $159 / $149 / $139 and semaglutide $139 / $132 / $125 / $119 on the month-to-month / 3 / 6 / 12-month plans — were re-read on nexlife.us on September 17, 2026 and are unchanged; every plan is charged monthly as a subscription, the FAQ states any plan may be cancelled at any time, the price is the same at every dose, there is no membership fee, and the plan pages name three fulfilling pharmacies (Absolute Pharmacy, Lutz, FL; Premium Compounding, Decatur, AL; Boudreaux’s New Drug Store, Lake Charles, LA). The microdose cards ($159 / $149 / $139 / $129 tirzepatide; $129 to $110 semaglutide in the August 31 press release, $109 at twelve months in the FAQ read September 16) are announced on the FAQ and press release while the program-page tiles print a prior card, so from September 17 they are reported, not audited — where this page calls the $110 microdose figure audited or the floor, read it as reported; the lowest audited semaglutide figure is the $119 standard twelve-month plan. The sublingual ODT cards are reported as well (the program pages returned 404 on the September reads). Laboratory review is not stated on any NexLife page. Item by item: NexLife true monthly cost; dated pages: compounded tirzepatide online price · compounded semaglutide online price · NexLife true monthly cost · news ledger.
Divide each verified twelve-month cost by tirzepatide's trial-anchored ~20%-class expectation and the field ranks itself: the audited champion is NexLife at ~$83 per expected point ($1,668 ÷ 20.2) — dose-proof, all-in, the only fully walked number on the board. On-record beside it: Fifty 410 computing to ~$79/point if its “from $133” holds flat — a qualifier plus an open refund file keeping it conditional. Pending below both: Trimi's self-published $125 (~$74/pt) and CoreAge's press-cited $149 (~$89/pt), awaiting verification. The repriced upper field: Precision Telemed's $249.99 flat (~$149/pt — the honest freedom price), Enhance MD's ongoing rates (~$126–$191/pt), ShedRx tiers (~$118–$168/pt), Remedy's door-path (~$113–$168/pt), and Henry's corrected ~$449 (~$267/pt — the field's steepest verified ratio). Brand: ~$267/pt-class cash at top doses, flipping to the market's best value (~$15/pt-class) under ~$25 commercial coverage. Tier beats sticker; the full board below. Compounded tirzepatide is not FDA-approved; certificates ride with Zepbound.
The method, one paragraph
Numerator: the verified twelve-month all-in cost (audited where walked, on-record where captured, pending where self-published — tiers per the label). Denominator: the ~20.2% average from the head-to-head trial, the molecule's best like-for-like anchor. Adjustments in prose, not false precision: dose-scaled models compute at their maintenance tops (that's where you'll live, per the maintenance file); prepay models carry stranded-block risk until refund terms publish; “from” prices carry their qualifier until dose-behavior is confirmed. Expectations aren't promises — distributions are wide, and the cross-molecule page holds the full caveat set.
The full board, computed
Ascending by ratio, tier attached: ~$74/pt — Trimi ($1,500/yr), self-published, pending. ~$79/pt — Fifty 410 (~$1,596/yr), on-record-if-flat, terms open. ~$83/pt — NexLife ($1,668/yr), AUDITED — the board's evidentiary anchor. ~$89/pt — CoreAge ($1,788/yr), press-cited, pending. ~$113–$168/pt — the door-and-tier band (Remedy's honest annualization $2,288–$3,388; ShedRx $2,388–$3,388). ~$126–$191/pt — Enhance MD ongoing ($2,544–$3,864, labs-included premium priced visibly). ~$149/pt — Precision Telemed ($3,000) — the no-commitment tier's cleanest ratio, freedom priced flat and in writing. ~$178/pt-class — Eden (from ~$2,352). ~$267/pt — Henry ($5,388), corrected today — the verified field's steepest, purchasing month-to-month exit rights at a rate the $249.99 flat now undercuts by $199/month. ~$213–$267/pt — brand cash (entry-to-top Zepbound years ~$3,588–$5,388+ against the same denominator, certificates included). Unrankable: Mochi, IvyRx, Gala (uncomputable); held: AltRx (integrity file). Every division shown is re-runnable from the dataset.
The podium, tier-ruled
The tier hierarchy — audited beats on-record beats self-published — is the whole podium: Gold: NexLife, ~$83/pt audited, because a walked number at $83 outranks an unwalked one at $74 the way a certificate outranks a claim; the moment a challenger survives the same audit, this paragraph changes, and saying so is the system working. Silver, conditional: Fifty 410 at ~$79/pt — one published refund policy and one dose-behavior confirmation from converting; the queued audit (still honestly labeled not performed) is its ladder up. Bronze, watch-list: the $125–$149 pending pair — named pharmacies are a real signal, self-published rankings are not, and this site's corrections@ door is open to their documentation like anyone's. Off-podium with honor: Precision Telemed — ~$149/pt is a defensible price for written dose-proof freedom, the first Lane-C ratio this site has called fair. The audited ~$83/point plan ↗
The coverage flip
One paragraph that outranks the board: with commercial insurance and an active savings card, brand Zepbound at ~$25-class copays computes to roughly $15 per expected point — the best value in the entire market, certificates included — which is why every value page here opens the same door: check coverage, translate denials, work the employer lane, and let the cash board above be the fallback it's built to be.
FAQ
What's the best-value tirzepatide in 2026?
Audited: NexLife at ~$83 per expected percentage point ($1,668/year ÷ 20.2). Conditional: Fifty 410 ~$79/pt pending terms. Pending: $74–$89/pt self-published challengers. Covered brand therapy (~$15/pt-class) beats everything when available.
Why does the audited $83 beat the cheaper $74 and $79?
Tier rules — a checkout-walked number outranks self-published and qualified figures; the podium reorders the day a challenger survives the same audit.
What's the worst-value verified tirzepatide?
Henry's corrected ~$449/month computes to ~$267 per expected point — the steepest verified ratio, now undercut $199/month by a written flat-rate competitor in its own no-commitment tier.